L3VLUP
ProSign in

NVAX · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

NVAXGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • NVAX
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterNVAXGILD
Q3 20206 holders, $258m25 holders, $14.2bn
Q4 20204 holders, $221m27 holders, $13.4bn
Q1 202110 holders, $1.5bn24 holders, $14.5bn
Q2 20218 holders, $1.6bn18 holders, $14.9bn
Q3 20214 holders, $609m20 holders, $16.4bn
Q4 20214 holders, $399m20 holders, $16.8bn
Q1 20225 holders, $121m28 holders, $13.2bn
Q2 20226 holders, $148m26 holders, $13.6bn
Q3 20223 holders, $34m24 holders, $13.3bn
Q4 20223 holders, $8.0m32 holders, $21.1bn
Q1 20232 holders, $12m27 holders, $21.8bn
Q2 20231 holders, $7.7m24 holders, $20.7bn
Q3 2023none listed holders, n.a.24 holders, $20.0bn
Q4 20231 holders, $7.3m22 holders, $21.5bn
Q1 20242 holders, $13m30 holders, $20.3bn
Q2 20246 holders, $163m28 holders, $18.5bn
Q3 20245 holders, $129m29 holders, $24.2bn
Q4 20242 holders, $520k28 holders, $25.9bn
Q1 20252 holders, $25m33 holders, $32.0bn
Q2 20252 holders, $24m27 holders, $30.9bn
Q3 20252 holders, $40m23 holders, $29.4bn
Q4 20251 holders, $1.3m25 holders, $34.3bn
Q1 20262 holders, $31m25 holders, $38.5bn
Q2 20261 holders, $36m26 holders, $34.2bn
NVAX

Novavax Inc

Holders
2
Reported value
$520k
Buyers
0
Sellers
2

Breadth -2 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
GILD

Gilead Sciences Inc

Holders
28
Reported value
$25.9bn
Buyers
14
Sellers
14

Breadth 0 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q4 2024

Among the 30 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only NVAX (2)

Farallon Capital Management LLC, Freestone Grove Partners LP

Only GILD (28)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, PDT Partners LLC, Point72 Asset Management LP, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, T. Rowe Price Associates Inc, Tudor Investment Corp, Two Sigma Advisers LP, Two Sigma Investments LP, Verition Fund Management LLC, and 3 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →